Compile Data Set for Download or QSAR
Report error Found 2800 for UniProtKB: Q15116
TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM491037(US10975049, Example 4 | (S) N-(4-(2-bromo-3-phenyl...)
Affinity DataIC50: 0.000100nMAssay Description:In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Princip...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetProgrammed cell death protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM491057(US10975049, Example 26 | N-(4-(2-bromo-3-phenylben...)
Affinity DataIC50: 0.000500nMAssay Description:In vitro activity evaluation: Cisbio PD-1/PD-L1 binding assay kit was applied for the detection method of in vitro enzymology level.Screening Princip...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM50548983(CHEMBL4795176 | US20230303494, Compound 5)
Affinity DataKd:  0.0160nMAssay Description:Example 40: In the experiment, the instrument OctectRED of Fortebio Company based on biofilm interferometry (BLI) technology was used to capture huma...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575561(US11459339, Example 41 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.0320nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575599(US11459339, Example 60 | (1s,1's,3s,3's)-3,3'-((((...)
Affinity DataIC50: 0.0340nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575553(US11459339, Example 37 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.0400nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM50587714(CHEMBL5182195)
Affinity DataIC50: 0.0400nMAssay Description:Inhibition of PD-1/PD-L1 interaction (unknown origin) by HTRF binding assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/18/2023
Entry Details
PubMed
TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM50567288(CHEMBL4865838)
Affinity DataIC50: 0.0510nMAssay Description:Inhibition of PD1/PD-L1 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM50567287(CHEMBL4862360)
Affinity DataIC50: 0.0580nMAssay Description:Inhibition of PD1/PD-L1 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2022
Entry Details Article
PubMed
TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575483(US11459339, Example 2 | US11459339, Example 4)
Affinity DataIC50: 0.0640nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575498(US11459339, Example 80 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.0820nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575493(US11459339, Example 7 | N,N'-(2,2'-dimethyl-[1,1'-...)
Affinity DataIC50: 0.0960nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM468371(US10806785, Example 11 | N,N′-(2-chloro-2...)
Affinity DataIC50: 0.100nMAssay Description:Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 μL. Compounds to be analyzed were first s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM395437((S)-1-((2-(2′-chloro-3′-(1,5-dimethyl-...)
Affinity DataIC50: 0.100nMAssay Description:Binding assays were conducted in a low volume white 384-well polystyrene plate in a final volume of 20 μL. Compounds to be analyzed were first s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575609(US11459339, Example 65 | (2S,2S)-1,1'-(((((2,2'-di...)
Affinity DataIC50: 0.120nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575505(US11459339, Example 13 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.130nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM711247(US12187713, Example 103)
Affinity DataIC50: 0.130nMAssay Description:The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/19/2025
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM711272(((2-(2-cyano-3'- (6-(difluoromethoxy)-5- ((3,3-di...)
Affinity DataIC50: 0.140nMAssay Description:The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/19/2025
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575486(US11459339, Example 74 | N,N'-2,2'-dimethyl[1,1'-b...)
Affinity DataIC50: 0.140nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575511(US11459339, Example 16 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.140nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575517(US11459339, Example 19 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.150nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575585(US11459339, Example 53 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.150nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575520(US11459339, Example 91 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.160nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575481(US11459339, Example 1 | N,N′-(2,2′-dim...)
Affinity DataIC50: 0.170nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575601(US11459339, Example 61 | (2'S)-(((((2,2'-dimethyl-...)
Affinity DataIC50: 0.180nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575483(US11459339, Example 2 | US11459339, Example 4)
Affinity DataIC50: 0.180nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM711248(((6-(difluoromethoxy)- 2-(3'-(5-((2- hydroxy-2- m...)
Affinity DataIC50: 0.190nMAssay Description:The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/19/2025
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM710780(US12187713, Example 2)
Affinity DataIC50: 0.200nMAssay Description:The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/19/2025
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575485(US11459339, Example 3 | N,N'-(2,2'-dimethyl-[1,1'-...)
Affinity DataIC50: 0.200nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM711334(((6-(difluoromethoxy)-2-(2,2'- dimethyl-3'-(4,5,6,...)
Affinity DataIC50: 0.200nMAssay Description:The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/19/2025
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM592995(US11578054, Example 1017)
Affinity DataIC50: 0.200nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575602(US11459339, Example 132 | (3R,3'R)-1,1'-(((((2,2'-...)
Affinity DataIC50: 0.200nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575587(US11459339, Example 54 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.210nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575547(US11459339, Example 34 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.210nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575581(US11459339, Example 51 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.220nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575569(US11459339, Example 45 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.220nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575595(US11459339, Example 58 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.220nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575567(US11459339, Example 44 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.240nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575571(US11459339, Example 46 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.25nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575603(US11459339, Example 62 | (2S,2'S,4R,4'R)-1,1'-((((...)
Affinity DataIC50: 0.25nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575605(US11459339, Example 63 | (3S,3'S)-4,4'(((((2,2'-di...)
Affinity DataIC50: 0.25nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575543(US11459339, Example 32 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.270nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575573(US11459339, Example 47 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.270nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575548(US11459339, Example 105 | (2R,2'R)-2,2'-((((((2,2'...)
Affinity DataIC50: 0.270nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575533(US11459339, Example 27 | (2S,2'S)-1,1'-(((((2,2'-d...)
Affinity DataIC50: 0.280nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575523(US11459339, Example 22 | dimethyl 2,2'-((((((2,2'-...)
Affinity DataIC50: 0.280nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575499(US11459339, Example 10 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.280nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575563(US11459339, Example 42 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.280nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM575565(US11459339, Example 43 | N,N'-(2,2'-dimethyl-[1,1'...)
Affinity DataIC50: 0.290nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Institute of Materia Medica, Chinese Academy of Medical Sciences

US Patent
LigandPNGBDBM711446(((2-(2'-chloro-3'-(5-(((2- hydroxyethyl)amino)meth...)
Affinity DataIC50: 0.290nMAssay Description:The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/19/2025
Entry Details
US Patent

Displayed 1 to 50 (of 2800 total ) | Next | Last >>
Jump to: